0001213900-23-065007 | 6-K | XBRL Viewer

	Six Months Ended June 30,				Three Months Ended June 30,
	2023		2022		2023		2022
	Unaudited
Numerator:
Allocation of loss attributable to ordinary shareholders		11,905		23,719		5,837		11,845
Denominator:
Weighted average Ordinary shares outstanding		32,910,446		19,222,423		44,383,474		19,505,246

Basic and diluted loss per share	$	0.36	$	1.23	$	0.13	$	0.61

The potential Ordinary shares that were excluded from the computation of diluted loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:

	Three and Six Months Ended June 30,
	2023		2022
	Unaudited

Ordinary share options		2,078,310		4,146,332
Warrants		413,263		374,315

		2,491,573		4,520,647

Interim Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (11,905)	$ (23,719)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	913	805
Non-cash financial expenses, net	813	146
Remeasurement of warrants classified as a liability	(201)
Share-based compensation expenses	1,970	2,539
Changes in assets and liabilities:
Prepaid expenses and other assets	950	1,584
Operating lease liabilities and right-of-use-assets, net	(22)
Trade payables	(238)	(1,748)
Accrued expenses and other liabilities	(561)	51
Net cash used in operating activities	(8,281)	(20,342)
Cash flows from investing activities:
Short-term and long-term deposits, net	(7,668)	10,245
Purchase of property and equipment	(195)	(1,185)
Net cash provided (used) by investing activities	(7,863)	9,060
Cash flows from financing activities:
Proceeds from issuance of ordinary shares, net	8,627	3,754
Proceeds from long-term debt, net		9,331
Payments due to long-term debt	(1,522)	(406)
Payment of fees due to modification of debt	(125)
Proceeds from issuance of pre-funded warrants	3,987	468
Proceeds from exercise of options	9	108
Net cash provided by financing activities	10,976	13,255
Increase (decrease) in cash, cash equivalents and restricted cash	(5,168)	1,973
Cash, cash equivalents and restricted cash at the beginning of the period	9,142	10,456
Cash, cash equivalents and restricted cash at the end of the period	3,974	12,429
Non-cash activities:
Modification of warrants	31
Credit line derivative	127
Property and equipment acquired by credit		42
Supplemental disclosures of cash flows:
Interest paid	492	77
Supplemental disclosures of cash flow information:
Cash and cash equivalents	3,396	11,640
Restricted cash	503	576
Restricted cash included in other long-term assets	75	213
Cash, cash equivalents and restricted cash at the end of the period	$ 3,974	$ 12,429

Basic and Diluted Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Ordinary Share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Schedule of basic and diluted net loss per ordinary share [Abstract]
Allocation of loss attributable to ordinary shareholders	$ 5,837	$ 11,845	$ 11,905	$ 23,719	$ 39,557
Weighted average Ordinary shares outstanding	44,383,474	19,505,246	32,910,446	19,222,423
Basic and diluted loss per share	$ 0.13	$ 0.61	$ 0.36	$ 1.23

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Leases (Tables)

6 Months Ended

Jun. 30, 2023

Leases [Abstract]

Schedule of Weighted Average Remaining Lease Terms and Discount Rates

The following is a summary of weighted average remaining lease terms and discount rates for all of the Company’s operating leases as of June 30, 2023:

Weighted average remaining lease term (years)			3.26
Weighted average discount rates			9.16	%

Schedule of Total Operating Lease Cost

For the six months ended June 30, 2023, the total operating lease cost and cash payments for operating leases were as follows:

Operating lease cost		$	582
Cash payments for operating leases		$	524

Schedule of Minimum Lease Payments

Minimum lease payments over the remaining lease periods as of June 30, 2023, are as follows:

The remainder of 2023	$	479
2024		403
2025		358
2026		349
2027		177

Total undiscounted lease payments		1,766
Less - imputed interest		(195	)

Present value of lease liabilities	$	1,571

Leases (Details) - Schedule of Minimum Lease Payments $ in Thousands	Jun. 30, 2023 USD ($)
Schedule of Minimum Lease Payments [Abstract]
The remainder of 2023	$ 479
2024	403
2025	358
2026	349
2027	177
Total undiscounted lease payments	1,766
Less - imputed interest	(195)
Present value of lease liabilities	$ 1,571

Line of Credit Arrangement

6 Months Ended

Jun. 30, 2023

Line of Credit Arrangement [Abstract]

LINE OF CREDIT ARRANGEMENT

NOTE 4:- LINE OF CREDIT ARRANGEMENT

Further to the discussion in Note 7 in the 2022 Consolidated Financial Statements regarding the secured line of credit agreement signed on April 5, 2022, with Kreos Capital VI (Expert Fund) LP (“Kreos”) (the “Credit Line” or “debt”), the Company entered into an amendment to the Credit Line on March 29, 2023 (the “Amendment”).

Pursuant to the Amendment, 70% of the remaining principal and interest repayments will be delayed and repaid on a monthly equal basis from August 2024 to May 2026. The amended secured credit line now bears an interest at the rate of 10%. In addition, the Company will pay to Kreos a restructuring fee consisting of 1% on the closing date of the Amendment and an incremental 3% at the maturity of the Amendment. In return for this additional deferral of repayment, Kreos has the right to receive a potential claw-back payment on account of the then outstanding principal amount (the “Claw-Back”). This Claw-Back mechanism will be triggered by additional incoming funds from future collaboration and partnership agreements or additional funding. If triggered, the minimum Claw-Back to be paid will be $1,500, but will not exceed $3,000.

The Company evaluated the amendment under ASC 470-50, “Debt - modification and extinguishment”, and concluded that the terms of the new debt and the original debt are not substantially different, therefore the debt restructuring is accounted as debt modification where no gain or loss was recognized.

During the six-month period ended on June 30, 2023, the Company recognized $813 of interest expenses related to the Credit Line, which were included as part of financial expenses in the Company’s statements of operations.

In addition, the Company’s debt includes Claw-Back feature that meets the definition of embedded derivative under ASC 815. Consequently, the embedded derivative was bifurcated and accounted for separately at fair value. The fair value of the derivative amounted to $127 as of March 29, 2023, and June 30, 2023. Changes in the fair value of the derivative liabilities are determined at each period end. The liability due to the derivative was classified under other long-term liabilities in the consolidated balance sheet as of June 30, 2023.

Further to the above, the outstanding warrants issued to Kreos were repriced and as a result bear an exercise price of $0.42 per share. As a result of the modification, the Company recorded an incremental value in the amount of $31, that was calculated based on the Black-Scholes option pricing model, which increased the additional paid-in capital against an offset of the long-term debt due to the Credit Line.

The Company incurred debt restructuring costs, which were fully paid in cash, and are presented as a direct deduction against the carrying amount of the debt and amortized to interest expense using the effective interest method.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Leases

6 Months Ended

Jun. 30, 2023

Leases [Abstract]

LEASES

NOTE 3:- LEASES

The Company leases substantially all of its office space and vehicles under operating leases. The Company’s leases have original lease periods expiring between 2023 and 2027. Some leases include one or more options to renew. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain. Lease payments included in the measurement of the lease liability are comprised of the following: the fixed non-cancelable lease payments, payments for optional renewal periods, where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early.

The following is a summary of weighted average remaining lease terms and discount rates for all of the Company’s operating leases as of June 30, 2023:

Weighted average remaining lease term (years)			3.26
Weighted average discount rates			9.16	%

For the six months ended June 30, 2023, the total operating lease cost and cash payments for operating leases were as follows:

Operating lease cost		$	582
Cash payments for operating leases		$	524

Minimum lease payments over the remaining lease periods as of June 30, 2023, are as follows:

The remainder of 2023	$	479
2024		403
2025		358
2026		349
2027		177

Total undiscounted lease payments		1,766
Less - imputed interest		(195	)

Present value of lease liabilities	$	1,571

Shareholders’ Equity (Details) - Schedule of the Total Share-Based Compensation Expense - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Shareholders’ Equity (Details) - Schedule of the Total Share-Based Compensation Expense [Line Items]
Total share-based compensation expense	$ 1,970	$ 2,539
Research and development [Member]
Shareholders’ Equity (Details) - Schedule of the Total Share-Based Compensation Expense [Line Items]
Total share-based compensation expense	1,022	1,193
Marketing and business development [Member]
Shareholders’ Equity (Details) - Schedule of the Total Share-Based Compensation Expense [Line Items]
Total share-based compensation expense	191	199
General and administrative [Member]
Shareholders’ Equity (Details) - Schedule of the Total Share-Based Compensation Expense [Line Items]
Total share-based compensation expense	$ 757	$ 1,147

General

6 Months Ended

Jun. 30, 2023

General [Abstract]

GENERAL

NOTE 1:- GENERAL

PolyPid Ltd. (the “Company”) was incorporated under the laws of Israel and commenced operations on February 28, 2008. The Company is a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. The Company’s product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, locally at predetermined release rates and durations over extended periods ranging from days to several months. The Company is initially focused on the development of its lead product candidate, D-PLEX, which incorporates an antibiotic for the prevention of surgical site infections (“SSIs”) in bone and soft tissue. Through June 30, 2023, the Company has been primarily engaged in research and development.

The Company’s wholly owned subsidiaries include a subsidiary in the United States (the “US Subsidiary”) and a subsidiary in Romania. The US Subsidiary’s operation focuses on marketing and business development of the Company’s operation in the United States.

The Company’s activities since inception have consisted of performing research and development activities. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to secure financing; obtain marketing approval from regulatory authorities; access potential markets; build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. The Company’s operations are funded by its shareholders and research and development grants and the Company intends to seek further private or public financing as well as make applications for further research and development grants for continuing its operations. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably.

In September 2022, the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX₁₀₀ (“SHIELD”) I Phase 3 trial. SHIELD I did not achieve its primary endpoint of reduction in SSIs, re-interventions due to SSIs and mortality: in the Intent to Treat population, the local administration of D-PLEX₁₀₀ and standard of care (“SoC”), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).

The Company expects to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business plan, the Company will need to complete Phase 3 clinical studies and certain development activities as well as manufacture the required clinical and commercial production batches in the pilot manufacturing plant. Further, the Company’s product candidates will require regulatory approval prior to commercialization, and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company.

As of June 30, 2023, the Company’s cash, cash equivalents and short-term deposits amounted to a total of $15,106. During the six-month period ended June 30, 2023, the Company incurred a loss of $11,905 and had negative cash flows from operating activities of $8,281. In addition, the Company had an accumulated deficit of $226,349 as of June 30, 2023.

Management plans to seek additional equity financing through private and public offerings or strategic partnerships and, in the longer term, by generating revenues from product sales.

The Company’s future operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies; (ii) the success of its research and development activities; (iii) manufacture of all required clinical and commercial production batches; (iv) marketing approval by the relevant regulatory authorities; and (v) market acceptance of the Company’s product candidates.

There can be no assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above.

Based on the abovementioned, as of the approval date of these interim consolidated financial statements, the Company has not raised the necessary funding in order to continue its activity for a period of at least one year. Therefore, these factors raise a substantial doubt about the Company’s ability to continue as a going concern. The interim condensed consolidated financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result should the Company be unable to continue as a going concern.

Interim Condensed Consolidated Statements of Shareholders’ Equity - USD ($)
$ in Thousands

Number of ordinary shares

Additional paid-in capital

Accumulated deficit

Total

Balance at Dec. 31, 2021

$ 210,847

$ (174,887)

$ 35,960

Balance (in Shares) at Dec. 31, 2021

18,756,570

Share-based compensation

2,539

Issuance of shares, net

^[1]

3,754

Issuance of shares, net (in Shares)

^[1]

768,622

Issuance of warrants

468

Exercise of options

108

Exercise of options (in Shares)

25,981

Net loss

(23,719)

Balances at Jun. 30, 2022

217,716

(198,606)

19,110

Balances (in Shares) at Jun. 30, 2022

19,551,173

Balance at Dec. 31, 2021

210,847

(174,887)

35,960

Balance (in Shares) at Dec. 31, 2021

18,756,570

Share-based compensation

4,307

Issuance of ordinary shares, net

^[2]

4,423

Issuance of ordinary shares, net (in Shares)

^[2]

1,065,057

Issuance of warrants

588

Exercise of options

108

Exercise of options (in Shares)

30,206

Net loss

(39,557)

Balances at Dec. 31, 2022

220,273

(214,444)

5,829

Balances (in Shares) at Dec. 31, 2022

19,851,833

Balance at Mar. 31, 2022

215,606

(186,761)

28,845

Balance (in Shares) at Mar. 31, 2022

19,470,757

Share-based compensation

1,266

Issuance of ordinary shares, net

^[3]

285

Issuance of ordinary shares, net (in Shares)

^[3]

57,722

Issuance of warrants

468

Exercise of options

Exercise of options (in Shares)

22,694

Net loss

(11,845)

Balances at Jun. 30, 2022

217,716

(198,606)

19,110

Balances (in Shares) at Jun. 30, 2022

19,551,173

Balance at Dec. 31, 2022

220,273

(214,444)

5,829

Balance (in Shares) at Dec. 31, 2022

19,851,833

Share-based compensation

1,970

Issuance of ordinary shares, net

^[4]

8,627

Issuance of ordinary shares, net (in Shares)

^[4]

18,808,029

Issuance of pre-funded warrants, net

^[5]

3,987

Issuance of pre-funded warrants, net (in Shares)

^[5]

Exercise of options

Exercise of options (in Shares)

34,309

Modification of warrants

Reclassification of pre-funded warrants to Liabilities

(2,106)

Reclassification of pre-funded warrants to Equity

1,905

Cashless exercise of pre-funded warrants

Cashless exercise of pre-funded warrants (in Shares)

10,354,532

Net loss

(11,905)

Balances at Jun. 30, 2023

234,696

(226,349)

8,347

Balances (in Shares) at Jun. 30, 2023

49,048,703

Balance at Mar. 31, 2023

231,919

(220,512)

11,407

Balance (in Shares) at Mar. 31, 2023

38,694,171

Share-based compensation

841

Modification of warrants

Reclassification of pre-funded warrants to Equity

1,905

Cashless exercise of pre-funded warrants

Cashless exercise of pre-funded warrants (in Shares)

10,354,532

Net loss

(5,837)

Balances at Jun. 30, 2023

$ 234,696

$ (226,349)

$ 8,347

Balances (in Shares) at Jun. 30, 2023

49,048,703

[1]	Net of issuance cost of $162.
[2]	Net of issuance costs of $222.
[3]	Net of issuance cost of $21 in cash.
[4]	Net of issuance cost of $734.
[5]	Net of issuance cost of $362.

Basic and Diluted Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2023

Basic and Diluted Loss Per Share [Abstract]

Schedule of Basic and Diluted Net Loss Per Ordinary Share

The following table sets forth the computation of the Company’s basic and diluted net loss per Ordinary share:

	Six Months Ended June 30,				Three Months Ended June 30,
	2023		2022		2023		2022
	Unaudited
Numerator:
Allocation of loss attributable to ordinary shareholders		11,905		23,719		5,837		11,845
Denominator:
Weighted average Ordinary shares outstanding		32,910,446		19,222,423		44,383,474		19,505,246

Basic and diluted loss per share	$	0.36	$	1.23	$	0.13	$	0.61

Schedule of Diluted Loss Per Share Attributable to Ordinary Shareholders

	Three and Six Months Ended June 30,
	2023		2022
	Unaudited

Ordinary share options		2,078,310		4,146,332
Warrants		413,263		374,315

		2,491,573		4,520,647

Line of Credit Arrangement (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023	Mar. 29, 2023
Line of Credit Arrangement (Details) [Line Items]
Principal and repayments delayed	70.00%
Percentage of interest	10.00%
Restructuring fee, percentage	1.00%
Percentage of maturity	3.00%
Interest expenses	$ 813
Derivative amount	$ 127	$ 127
Exercise price of warrants (in Dollars per share)	$ 0.42
Warrant modification	$ 31
Claw-Back [Member] \| Minimum [Member]
Line of Credit Arrangement (Details) [Line Items]
Amount paid	1,500
Claw-Back [Member] \| Maximum [Member]
Line of Credit Arrangement (Details) [Line Items]
Amount paid	$ 3,000

Commitments and Contingent Liabilities

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

NOTE 5:- COMMITMENTS AND CONTINGENT LIABILITIES

In connection with its research and development programs, through June 30, 2023, the Company received participation payments from the Israel Innovation Authority of the Ministry of Economy in Israel (“IIA”) in the aggregate amount of $4,888. In return for IIA’s participation, the Company is committed to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate.

Through June 30, 2023, no royalties have been paid or accrued.

Interim Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development, net	$ 3,960	$ 8,398	$ 7,754	$ 17,095
Marketing and business development	357	923	742	1,698
General and administrative	1,503	2,243	3,112	4,723
Operating loss	5,820	11,564	11,608	23,516
Financial expense, net	7	281	262	203
Loss before income tax	5,827	11,845	11,870	23,719
Income tax expenses	10		35
Net loss	$ 5,837	$ 11,845	$ 11,905	$ 23,719
Basic loss per ordinary share (in Dollars per share)	$ 0.13	$ 0.61	$ 0.36	$ 1.23
Weighted average number of ordinary shares used in computing basic loss per share (in Shares)	44,383,474	19,505,246	32,910,446	19,222,423

Commitments and Contingent Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Participation payments (in Dollars)	$ 4,888
Percentage of sales	3.00%
Percentage of grant received	100.00%

Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	710,016
Options exercisable	508,732
April 2016 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	5,975
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 3.1
Options exercisable	5,975
Exercisable	April 2026
December 2016 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	7,170
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 3.93
Options exercisable	7,170
Exercisable	December 2026
June 2017 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	197,722
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 4.1
Options exercisable	197,722
Exercisable	June 2027
November 2017 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	17,925
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 0.77
Options exercisable	17,925
Exercisable	November 2027
August 2019 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	71,700
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 0.77
Options exercisable	71,700
Exercisable	August 2029
June 2020 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	64,530
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 2.84
Options exercisable	64,530
Exercisable	June 2030
April 2021 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	62,741
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 2.03
Options exercisable	62,741
Exercisable	April 2031
August 2021 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	15,000
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 0.77
Options exercisable	8,719
Exercisable	August 2031
December 2021 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	10,000
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 6.8
Options exercisable	4,975
Exercisable	December 2031
May 2022 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	65,625
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 1.37
Options exercisable	65,625
Exercisable	May 2032
November 2022 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	5,000
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 1.05
Options exercisable	1,650
Exercisable	November 2032
February 2023 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	16,000
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 0.81
Options exercisable
Exercisable	February 2033
May 2023 [Member]
Shareholders’ Equity (Details) - Schedule of Outstanding Options Granted To Non-Employees [Line Items]
Options outstanding	170,628
Average Exercise price per share (in Dollars per share) \| $ / shares	$ 0.6
Options exercisable
Exercisable	May 2033

Shareholders’ Equity (Details) - Schedule of Status of Options to Employees under the Company’s Option Plan $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Schedule of Status of Options to Employees Under the Company'S Option Plan [Abstract]
Number of options, Outstanding beginning balance \| shares	3,303,346
Weighted average exercise price, Outstanding beginning balance \| $ / shares	$ 1.92
Aggregate intrinsic value, Outstanding beginning balance \| $	$ 115
Weighted average remaining contractual life (years), Outstanding beginning balance	6 years 1 month 20 days
Number of options, Granted \| shares	114,500
Weighted average exercise price, Granted \| $ / shares	$ 0.71
Aggregate intrinsic value, Granted \| $
Number of options, Exercised \| shares	(34,309)
Weighted average exercise price, Exercised \| $ / shares	$ 0.23
Aggregate intrinsic value, Exercised \| $	$ 12
Number of options, Forfeited and expired \| shares	(795,172)
Weighted average exercise price, Forfeited and expired \| $ / shares	$ 3.65
Number of options, Outstanding ending balance \| shares	2,588,365
Weighted average exercise price, Outstanding ending balance \| $ / shares	$ 1.36
Aggregate intrinsic value, Outstanding ending balance \| $
Weighted average remaining contractual life (years), Outstanding ending balance	6 years 4 months 20 days
Number of options, Exercisable options \| shares	1,569,578
Weighted average exercise price, Exercisable options \| $ / shares	$ 1.74
Aggregate intrinsic value, Exercisable options \| $
Weighted average remaining contractual life (years), Exercisable options	4 years 11 months 8 days
Number of options, Vested and expected to vest \| shares	2,588,365
Weighted average exercise price, Vested and expected to vest \| $ / shares	$ 1.36
Aggregate intrinsic value, Vested and expected to vest \| $
Weighted average remaining contractual life (years), Vested and expected to vest	6 years 4 months 20 days

Interim Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 3,396	$ 8,552
Short-term deposits	11,710	4,042
Restricted deposits	503	511
Prepaid expenses and other current assets	144	1,089
Total current assets	15,753	14,194
LONG-TERM ASSETS:
Property and equipment, net	8,529	9,247
Operating lease right-of-use assets	1,892	2,431
Other long-term assets	89	99
Total long-term assets	10,510	11,777
Total assets	26,263	25,971
CURRENT LIABILITIES:
Current maturities of long-term debt	2,068	4,024
Accrued expenses and other current liabilities	1,842	2,429
Trade payables	903	1,141
Current maturities of operating lease liabilities	638	959
Total current liabilities	5,451	8,553
LONG-TERM LIABILITIES:
Long-term debt	8,538	7,574
Deferred revenues	2,548	2,548
Long-term operating lease liabilities	933	1,173
Other liabilities	446	294
Total long-term liabilities	12,465	11,589
COMMITMENTS AND CONTINGENT LIABILITIES
SHAREHOLDERS’ EQUITY:
Ordinary shares with no par value - Authorized: 107,800,000 and 47,800,000 shares at June 30, 2023 (unaudited) and December 31, 2022, respectively; Issued and outstanding: 49,048,703 and 19,851,833 shares at June 30, 2023 (unaudited) and December 31, 2022, respectively
Additional paid-in capital	234,696	220,273
Accumulated deficit	(226,349)	(214,444)
Total shareholders’ equity	8,347	5,829
Total liabilities and shareholders’ equity	$ 26,263	$ 25,971

Shareholders’ Equity

6 Months Ended

Jun. 30, 2023

Shareholders’ Equity [Abstract]

SHAREHOLDERS’ EQUITY

NOTE 6:- SHAREHOLDERS’ EQUITY

Ordinary share capital (with no par value) is composed as follows:

June 30, 2023

December 31, 2022

Unaudited

Audited

Authorized

Issued and
outstanding

Authorized

Issued and
outstanding

Number of shares

Ordinary shares

107,800,000

49,048,703

47,800,000

19,851,833

In July 2021, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell, from time to time, its Ordinary shares, no par value (the “Ordinary Shares”), through the Agent in an At The Market offering (“ATM’”), as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, for an aggregate offering price of up to $45,000, which was subsequently reduced to $8,707 on May 19, 2023.

During the six-month period ended June 30, 2023, the Company sold 1,949,029 Ordinary Shares under the ATM for a total amount of $2,212, net of issuance cost in the amount of $68.

On March 29, 2023, the Company entered into a private placement of unregistered pre-funded warrants to purchase up to 10,357,139 Ordinary shares (the “PFW”), at a price of $0.4199 per PFW with certain of the Company’s existing shareholders. The PFWs have an exercise price of $0.0001 per Ordinary share. Accordingly, the consideration for the PFWs amounted to $3,987, net of related placement fees and other offering expenses which amounted to a total of $362. In accordance with ASC No. 480, “Distinguishing Liabilities from Equity” (“ASC 480”), and ASC No. 815-40, “Derivatives and Hedging” (“ASC 815”), the PFWs were qualified for equity accounting.

On March 31, 2023, the Company closed a public offering which was comprised of 16,859,000 Ordinary shares (inclusive of 2,199,000 Ordinary shares pursuant to the full exercise of an overallotment option granted to the underwriters), at a public offering price of $0.42 per share (the “Public Offering”). The proceeds to the Company from the Public Offering were $6,415, net of underwriting commissions and other offering expenses which amounted to $666.

Following the Public Offering, the Company did not have a sufficient number of authorized Ordinary shares to cover 5,013,446 PFWs, and as a result, in accordance with ASC 815-40, these PFWs, which amounted to $2,106, were classified as a liability at fair value.

On May 5, 2023, the shareholders of the Company approved to increase the Company’s authorized share capital by 60,000,000, from 47,800,000 to 107,800,000 Ordinary shares, and as a result, in accordance with ASC 480 and 815-40, these PFWs were classified under equity accounting at their fair value, which amounted to $1,905. The change in the PFWs fair value was accounted for as financial expenses in the amount of $201.

On May 11, 2023, all of the PFWs were exercised into 10,354,532 Ordinary shares on a cashless basis.

Share option plan:

Through June 30, 2023, the Company authorized through its 2012 Share Option Plan the grant of 4,672,094 options to Ordinary shares to its officers, directors, advisors, management and other employees. The options granted generally have a four-year or three-year vesting period and expire ten years after the date of grant. Options granted under the Company’s option plan that are cancelled or forfeited before expiration become available for future grant.

As of June 30, 2023, 1,206,447 of the Company’s options were available for future grants.

During the first quarter of 2023, the Company decreased the exercise price of 2,021,599 options granted to all employees and a consultant under the 2012 Share Option Plan. As of the modification date, the options can be exercised for $0.77 (the “Repricing”). Following the Repricing the Company accounted for an incremental value in the total amount of $562, in which $307 was recognized as of the modification date due to vested options, and the rest of the amount will be expensed based on the vesting conditions of each grant.

On May 5, 2023, the Company’s board of directors also approved a similar exercise price decrease of 504,169 options previously granted to the Company’s Chief Executive Officer and board members. Therefore, the Company accounted for an incremental value in the total amount of $63, of which $50 was recognized as of the modification date due to vested options, and the rest of the amount will be expensed based on the vesting conditions of each grant.

A summary of the status of options to employees under the Company’s 2012 Share Option Plan as of and for the six-month period ended June 30, 2023, and changes during the period then ended is presented below (unaudited):

	Number of options			Weighted average exercise price		Aggregate intrinsic value		Weighted average remaining contractual life (years)

Outstanding at beginning of period		3,303,346		$	1.92	$	115		6.14
Granted		114,500		$	0.71		-
Exercised		(34,309	)	$	0.23	$	12
Forfeited and expired		(795,172	)	$	3.65

Outstanding at end of period		2,588,365		$	1.36	$	-		6.39

Exercisable options		1,569,578		$	1.74	$	-		4.94

Vested and expected to vest		2,588,365		$	1.36	$	-		6.39

The Black-Scholes option pricing model assumptions used to value the employee share options at the grant dates are presented in the following table for the six-month period ended June 30, 2023:

Dividend yield (%)			0
Expected volatility (%)			92.59-95.67
Risk-free interest rate (%)			3.38-3.73
Expected term (in years)			5.7-6.1

The total share-based compensation expense recognized by the Company’s departments:

	Six Months Ended June 30,
	2023		2022
	Unaudited

Research and development	$	1,022	$	1,193
Marketing and business development		191		199
General and administrative		757		1,147

	$	1,970	$	2,539

As of June 30, 2023, there were unrecognized compensation costs of $4,692, which are expected to be recognized over a weighted average period of approximately 2.15 years.

Options issued to non-employees (including directors and consultants):

Outstanding options granted to non-employees as of June 30, 2023, were as follows (unaudited):

Grant date	Options outstanding as of June 30, 2023		Average Exercise price per share ($)		Options exercisable as of June 30, 2023		Exercisable through

April 2016		5,975	$	3.10		5,975	April 2026
December 2016		7,170	$	3.93		7,170	December 2026
June 2017		197,722	$	4.10		197,722	June 2027
November 2017		17,925	$	0.77		17,925	November 2027
August 2019		71,700	$	0.77		71,700	August 2029
June 2020		64,530	$	2.84		64,530	June 2030
April 2021		62,741	$	2.03		62,741	April 2031
August 2021		15,000	$	0.77		8,719	August 2031
December 2021		10,000	$	6.80		4,975	December 2031
May 2022		65,625	$	1.37		65,625	May 2032
November 2022		5,000	$	1.05		1,650	November 2032
February 2023		16,000	$	0.81		-	February 2033
May 2023		170,628	$	0.60		-	May 2033

		710,016				508,732

Warrants:

As of June 30, 2023, all warrants are exercisable into Ordinary shares, in which the outstanding issued warrants as of June 30, 2023, were as follows (unaudited):

Grant date	Warrants outstanding as of June 30, 2023		Average Exercise price per share ($)		Warrants exercisable as of June 30, 2023		Exercisable through

August 2019		200,596	$	15.95		200,596	August 2023
September 2020		17,925	$	16.00		17,925	September 2024
April 2022		155,794	$	*) 0.42		155,794	April 2029
July 2022		38,948	$	*) 0.42		38,948	July 2029

		413,263				413,263

Following the modification mentioned in Note 4.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

Leases (Details) - Schedule of Weighted Average Remaining Lease Terms and Discount Rates	Jun. 30, 2023
Schedule of Weighted Average Remaining Lease Terms and Discount Rates [Abstract]
Weighted average remaining lease term (years)	3 years 3 months 3 days
Weighted average discount rates	9.16%

Shareholders’ Equity (Details) - Schedule of Black-Scholes Option Pricing Model Assumptions Used To Value	6 Months Ended
	Jun. 30, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Dividend yield (%)	0.00%
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility (%)	92.59%
Risk-free interest rate (%)	3.38%
Expected term (in years)	5 years 8 months 12 days
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility (%)	95.67%
Risk-free interest rate (%)	3.73%
Expected term (in years)	6 years 1 month 6 days

Accounting Policies, by Policy (Policies)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Basis of presentation and summary of significant accounting policies

Basis of presentation and summary of significant accounting policies:

The accompanying interim condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States and are consistent in all material respects with those applied in the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 31, 2023.

The preparation of interim condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and judgments that affect the amounts reported in the interim condensed consolidated financial statements and accompanying notes. Significant items subject to such estimates and assumptions, but are not limited to, the fair value of financial assets and liabilities, the useful lives of property and equipment and the determination of the fair value of the Company’s share-based compensation. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from those estimates.

The interim financial information is unaudited, but reflects all normal recurring adjustments that are, in the opinion of management, necessary to fairly present the information set forth herein. The interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 20-F for the year ended December 31, 2022 (the “2022 Consolidated Financial Statements”). Interim results are not necessarily indicative of the results for a full year.

There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2022.

Basic and diluted loss per share

Basic and diluted loss per share:

The Company’s basic loss per share is calculated by dividing the loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted loss per share is the same as basic loss per share in periods when the effects of potentially dilutive shares of ordinary shares are anti-dilutive.

Fair value of financial instruments

Fair value of financial instruments:

Under U.S. GAAP, fair value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction between market participants and requires that assets and liabilities carried at fair value are classified and disclosed in the following three categories:

	Level 1 -	Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities.
	Level 2 -	Include other inputs that are directly or indirectly observable in the marketplace.
	Level 3 -	Unobservable inputs which are supported by little or no market activity.

The carrying amounts of cash and cash equivalents, restricted cash, short-term deposits, long-term deposits, other current assets, trade payables, accrued expenses and other current and non-current liabilities approximate their fair value due to the short-term maturity of such instruments.

Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates.

Recently adopted accounting pronouncements

Recently adopted accounting pronouncements:

As an “Emerging Growth Company”, the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act.

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to its business or that no material effect is expected on the condensed consolidated financial statements as a result of their future adoption.

Significant Accounting Policies

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and summary of significant accounting policies:

Basic and diluted loss per share:

Fair value of financial instruments:

	Level 1 -	Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities.
	Level 2 -	Include other inputs that are directly or indirectly observable in the marketplace.
	Level 3 -	Unobservable inputs which are supported by little or no market activity.

Recently adopted accounting pronouncements:

Leases (Details) - Schedule of Total Operating Lease Cost $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Schedule of Total Operating Lease Cost [Abstract]
Operating lease cost	$ 582
Cash payments for operating leases	$ 524

General (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
General (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
General [Abstract]
Description of administration	the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX100 (“SHIELD”) I Phase 3 trial. SHIELD I did not achieve its primary endpoint of reduction in SSIs, re-interventions due to SSIs and mortality: in the Intent to Treat population, the local administration of D-PLEX100 and standard of care (“SoC”), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).
Cash equivalents and short-term deposits		$ 15,106		$ 15,106
Income loss		(5,837)	$ (11,845)	(11,905)	$ (23,719)	$ (39,557)
Net cash used in operating activities				(8,281)	$ (20,342)
Accumulated deficit		$ (226,349)		$ (226,349)		$ (214,444)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Shareholders’ Equity (Details) - Schedule of Ordinary Share Capital - shares	Jun. 30, 2023	Dec. 31, 2022
Schedule of Ordinary Share Capital [Abstract]
Ordinary shares, Authorized	107,800,000	47,800,000
Ordinary shares, Issued and outstanding	49,048,703	19,851,833

Interim Condensed Consolidated Statements of Operations (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Diluted loss per ordinary share (in Dollars per share)	$ 0.13	$ 0.61	$ 0.36	$ 1.23
Weighted average number of ordinary shares used in computing diluted loss per share (in Shares)	44,383,474	19,505,246	32,910,446	19,222,423

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

Shareholders’ Equity (Details) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended				3 Months Ended	6 Months Ended
	May 11, 2023	May 05, 2023	Mar. 31, 2023	May 05, 2022	May 19, 2023	Mar. 31, 2023	Mar. 29, 2023	Jul. 31, 2021	Mar. 31, 2023	Jun. 30, 2023
Shareholders’ Equity (Details) [Line Items]
Aggregate offering price					$ 8,707			$ 45,000
Total amount for ATM										$ 2,212
Net of issuance cost										$ 68
Purchase up to (in Shares)							10,357,139
Price per share (in Dollars per share)							$ 0.4199
Exercise price per share (in Dollars per share)							$ 0.0001
Total consideration, net							$ 3,987
Other offering expenses						$ 666	$ 362
Ordinary shares issued (in Shares)	10,354,532					16,859,000				5,013,446
Offering price per share (in Dollars per share)						$ 0.42
Public offering proceeds						$ 6,415
Fair value liability		$ 1,905								$ 2,106
Authorized share capital (in Shares)		60,000,000
Finance expenses		$ 201
Stock options available for future grants (in Shares)										1,206,447
Share options granted (in Shares)									2,021,599
Stock option exercise price (in Shares)			0.77
Total amount									$ 562
Vested option amount									$ 307
Vested option amount
Unrecognized compensation costs										$ 4,692
recognized over a weighted average period										2 years 1 month 24 days
Over-Allotment Option [Member]
Shareholders’ Equity (Details) [Line Items]
Ordinary shares issued (in Shares)						2,199,000
2012 Share Option Plan [Member]
Shareholders’ Equity (Details) [Line Items]
Grant of options shares (in Shares)										4,672,094
Ordinary Shares [Member]
Shareholders’ Equity (Details) [Line Items]
Ordinary Shares, Sold (in Shares)										1,949,029
Minimum [Member]
Shareholders’ Equity (Details) [Line Items]
Authorized share capital (in Shares)		47,800,000
Maximum [Member]
Shareholders’ Equity (Details) [Line Items]
Authorized share capital (in Shares)		107,800,000
Board of Directors [Member]
Shareholders’ Equity (Details) [Line Items]
Total amount				$ 63
Additional options shares (in Shares)				504,169
Vested option amount				$ 50

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2023
Document Information Line Items
Entity Registrant Name	PolyPid Ltd.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001611842
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity File Number	001-38428

Interim Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Ordinary shares, par value (in Dollars per share)
Ordinary shares, shares authorized	107,800,000	47,800,000
Ordinary shares, shares issued	49,048,703	19,851,833
Ordinary shares, shares outstanding	49,048,703	19,851,833

Basic and Diluted Loss Per Share (Details) - Schedule of Diluted Loss Per Share Attributable to Ordinary Shareholders - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Total	2,491,573	4,520,647	2,491,573	4,520,647
Warrants [Member]
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Total	413,263	374,315	413,263	374,315
Ordinary Share options [Member]
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Total	2,078,310	4,146,332	2,078,310	4,146,332

Shareholders’ Equity (Tables)

6 Months Ended

Jun. 30, 2023

Shareholders’ Equity [Abstract]

Schedule of Ordinary Share Capital

Ordinary share capital (with no par value) is composed as follows:

June 30, 2023

December 31, 2022

Unaudited

Audited

Authorized

Issued and
outstanding

Authorized

Issued and
outstanding

Number of shares

Ordinary shares

107,800,000

49,048,703

47,800,000

19,851,833

Schedule of Status of Options to Employees under the Company’s Option Plan

	Number of options			Weighted average exercise price		Aggregate intrinsic value		Weighted average remaining contractual life (years)

Outstanding at beginning of period		3,303,346		$	1.92	$	115		6.14
Granted		114,500		$	0.71		-
Exercised		(34,309	)	$	0.23	$	12
Forfeited and expired		(795,172	)	$	3.65

Outstanding at end of period		2,588,365		$	1.36	$	-		6.39

Exercisable options		1,569,578		$	1.74	$	-		4.94

Vested and expected to vest		2,588,365		$	1.36	$	-		6.39

Schedule of Black-Scholes Option Pricing Model Assumptions Used To Value

The Black-Scholes option pricing model assumptions used to value the employee share options at the grant dates are presented in the following table for the six-month period ended June 30, 2023:

Dividend yield (%)			0
Expected volatility (%)			92.59-95.67
Risk-free interest rate (%)			3.38-3.73
Expected term (in years)			5.7-6.1

Schedule of the Total Share-Based Compensation Expense

The total share-based compensation expense recognized by the Company’s departments:

	Six Months Ended June 30,
	2023		2022
	Unaudited

Research and development	$	1,022	$	1,193
Marketing and business development		191		199
General and administrative		757		1,147

	$	1,970	$	2,539

Schedule of Outstanding Options Granted To Non-Employees

Outstanding options granted to non-employees as of June 30, 2023, were as follows (unaudited):

Grant date	Options outstanding as of June 30, 2023		Average Exercise price per share ($)		Options exercisable as of June 30, 2023		Exercisable through

April 2016		5,975	$	3.10		5,975	April 2026
December 2016		7,170	$	3.93		7,170	December 2026
June 2017		197,722	$	4.10		197,722	June 2027
November 2017		17,925	$	0.77		17,925	November 2027
August 2019		71,700	$	0.77		71,700	August 2029
June 2020		64,530	$	2.84		64,530	June 2030
April 2021		62,741	$	2.03		62,741	April 2031
August 2021		15,000	$	0.77		8,719	August 2031
December 2021		10,000	$	6.80		4,975	December 2031
May 2022		65,625	$	1.37		65,625	May 2032
November 2022		5,000	$	1.05		1,650	November 2032
February 2023		16,000	$	0.81		-	February 2033
May 2023		170,628	$	0.60		-	May 2033

		710,016				508,732

Schedule of Warrants Exercisable Into Ordinary Shares

As of June 30, 2023, all warrants are exercisable into Ordinary shares, in which the outstanding issued warrants as of June 30, 2023, were as follows (unaudited):

Grant date	Warrants outstanding as of June 30, 2023		Average Exercise price per share ($)		Warrants exercisable as of June 30, 2023		Exercisable through

August 2019		200,596	$	15.95		200,596	August 2023
September 2020		17,925	$	16.00		17,925	September 2024
April 2022		155,794	$	*) 0.42		155,794	April 2029
July 2022		38,948	$	*) 0.42		38,948	July 2029

		413,263				413,263

Following the modification mentioned in Note 4.